Repair Abuses of MSP Payments (RAMP) Act
Summary
The RAMP Act (S.3816) is an early-stage bill that would restrict MSP private litigation to group health plans only. This concentrates legal risk on major group health insurers $UNH, $CI, $HUM, and $CVS while removing liability from workers' comp, auto, and liability insurers. The bill is in committee with one cosponsor and a House companion — low near-term passage probability, but the directional impact is clear: group health insurers face higher expected litigation costs if the bill advances.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.RAMP Act would restrict MSP private cause of action to group health plans only, removing workers' comp, auto, and liability insurers from litigation exposure.
- 2.No spending or funding involved — pure liability/legal risk redistribution bill.
- 3.Group health insurers $UNH, $CI, $HUM, $CVS face concentrated litigation costs; property-casualty insurers are structural beneficiaries.
- 4.Bill is early-stage (referred to committee, 1 cosponsor, House companion) — low near-term passage probability but directional risk for group health insurers is clear.
- 5.All four group health tickers have rallied significantly over the past 30 days (UNH +35.22%, HUM +38.55%) — current prices do not appear to reflect this legislative risk.
Market Implications
For investors in group health insurers (, $CI, $HUM, $CVS), the RAMP Act represents a negative regulatory overhang that is not yet priced into current levels. UNH at $365.88 (30-day +35.22%) and HUM at $240.23 (30-day +38.55%) have substantial recent gains that could unwind on any sign of committee markup. P&C insurers ($TRV, $ALL, $PGR) are structural beneficiaries — removal from MSP litigation reduces their legal costs and settlement exposure. Monitor Senate Finance Committee schedule and potential hearings on S.3816; any markup activity would be a near-term catalyst for group health insurer underperformance relative to the property-casualty sector.
Full Analysis
The RAMP Act (S.3816), introduced February 10, 2026 by Sen. Tim Scott (R-SC) with one Democratic cosponsor (Sen. Hassan), would amend the Medicare Secondary Payer statute to restrict the private cause of action from applying to all "primary plans" to only "group health plans." Currently, plaintiffs can sue any primary payer — including workers' compensation, auto insurance, liability insurance, and no-fault insurance — for failing to pay primary or reimburse Medicare. This bill would carve out non-group-health plans entirely, concentrating all private MSP litigation risk on group health insurers.
There is no funding authorized or appropriated — this is a liability and legal risk bill, not a spending bill. The mechanism is a statutory restriction on who can be sued, shifting the burden of proof and liability concentration. The money trail runs through increased legal defense costs, settlement payouts, and compliance costs for group health insurers, while every other primary plan type (workers' comp, auto, liability) is immunized from MSP private suits.
The structural winners are property & casualty insurers ($TRV, $ALL, $PGR), workers' compensation carriers, and liability insurers — they are removed from MSP litigation entirely. The losers are the top group health insurers: (UnitedHealthcare), $CI (Cigna), $HUM (Humana), and $CVS (Aetna). Humana has the smallest group health exposure relative to its Medicare Advantage book, so the bearish impact is tempered. Real market data shows all four tickers have rallied over the past 30 days (UNH +35.22%, HUM +38.55%, CI +7.94%, CVS +15.97%) — prices reflect other factors (likely earnings, Medicare Advantage rate updates, or sector rotation) but do not yet price in this legislative risk.
The bill is early stage: referred to Senate Finance Committee, with a House companion (HR4056) referred to Ways & Means and Energy & Commerce. Low legislative velocity (2 actions, same day), one cosponsor, no hearings scheduled. Passage probability is low in the current Congress, but this bill signals a long-term trend toward narrowing MSP liability — a risk factor for group health insurers that should be monitored as the bill advances through committee markup.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Same MSP litigation restriction — group health plans become the sole private cause of action target for failure to provide primary payment or reimbursement.
Who must act
Cigna's group health insurance business (commercial, employer-sponsored plans).
What happens
Increased legal and settlement costs concentrated on Cigna's group health book, removing the liability spread previously shared across all primary plan types.
Stock impact
Cigna's group health insurance segment is a core revenue driver. Cigna's current price $287.94 is below the 52-week high of $350 and has a 30-day return of +7.94%. The bill adds a regulatory overhang on the group health portion of Cigna's business.
What the bill does
Same MSP litigation restriction — group health plans become sole defendant class for private cause of action.
Who must act
Humana's group health and employer group plans segment.
What happens
Increased litigation risk and compliance costs concentrated on Humana's group health business.
Stock impact
Humana generates majority of revenue from Medicare Advantage (which is Medicare, not group health) — its group health exposure is smaller than competitors', limiting the direct impact. Humana current price $240.23, 30-day return +38.55%, near middle of 52-week range ($163.11–$315.35). The bill is less impactful on Humana's primary revenue stream, but still a legal headwind.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Protecting Health Care and Lowering Costs Act of 2025
Medicare for All Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.